Johnson & Johnson (SNSE:JNJ)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 603.10T +36.6% |
| Revenue (ttm) | 96.18T +7.8% |
| Net Income | 15.58T -35.9% |
| EPS | 6,375.49 -36.4% |
| Shares Out | n/a |
| PE Ratio | 38.80 |
| Forward PE | 22.04 |
| Dividend | 4,966.64 (2.03%) |
| Ex-Dividend Date | Nov 24, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 248.61 |
| Day's Range | n/a |
| 52-Week Range | 191.05 - 273.04 |
| Beta | 0.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 13, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally
Johnson & Johnson’s ($JNJ) rally has me holding off, despite an improving business. The global healthcare products maker raised its full-year guidance in the Q3 2026 earnings report released on…
Johnson & Johnson reports results from Phase 3 FUZION study
Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA, or guselkumab, maintained or improved fistula remission through 48 weeks in adults with Crohn’s disease, or…
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings...
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $JNJ--JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law.
Johnson & Johnson price target raised to $287 from $275 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Johnson & Johnson (JNJ) to $287 from $275 and keeps an Overweight rating on the shares. With 100% deal…
Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pil...
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Johnson & Johnson price target lowered to $292 from $294 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Johnson & Johnson to $292 from $294 and keeps an Overweight rating on the shares. The company posted “a generally in-line” Q3…
Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)
China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.
Johnson & Johnson price target lowered to $280 from $290 at RBC Capital
RBC Capital lowered the firm’s price target on Johnson & Johnson to $280 from $290 and keeps an Outperform rating on the shares. The stock’s 6% decline after in-line results…
Johnson & Johnson price target lowered to $272 from $276 at Leerink
Leerink lowered the firm’s price target on Johnson & Johnson to $272 from $276 and keeps an Outperform rating on the shares. Although 2027 results will be constrained by certain…
Johnson & Johnson price target lowered to $275 from $282 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Johnson & Johnson to $275 from $282 and keeps a Neutral rating on the shares, stating that the company delivered…
Johnson & Johnson price target lowered to $275 from $282 at Wells Fargo
Wells Fargo lowered the firm’s price target on Johnson & Johnson to $275 from $282 and keeps an Overweight rating on the shares. Despite Q3 beat/2026 guide raise, J&J was…
Johnson & Johnson price target lowered to $275 from $282 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Johnson & Johnson to $275 from $282 and keeps an Overweight rating on the shares. Despite Q3 beat/2026 guide…
Johnson & Johnson price target raised to $270 from $261 at Bernstein
Bernstein raised the firm’s price target on Johnson & Johnson to $270 from $261 and keeps a Market Perform rating on the shares. The firm notes J&J reported a solid…
Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
Johnson & Johnson executive vice president and CFO Joe Wolk discusses the company's third-quarter earnings, raising its full-year guidance, a potential spinoff of its DePuy Synthes orthopedics unit, a...
J&J raises its forecast again. CFO Joe Wolk on what's driving it
Johnson & Johnson raised its full-year forecast again on October 13, 2026, and CFO Joe Wolk tells Yahoo Finance's Julie Hyman that pharmaceuticals led the way, with oncology up 17% and immunology retu...
Johnson & Johnson shares fall following earnings
Johnson & Johnson stock is tumbling despite the company raising its forecast again for full-year earnings and revenue.
Tuesday's First Moves: WFC Mixed Earnings, JNJ Beat & Raise, DPZ Slides
JPMorgan Chase (JPM) earnings showed a double miss and gained after the opening bell while Wells Fargo (WFC) showed mixed results and traded lower. Diane King Hall offers a closer look into the latter...
J&J Medtech Sales Disappoint, Considers Orthopedic Spinoff
Johnson & Johnson reported a 2.5% rise in medical technology sales, missing estimates, and is leaning toward a spinoff of its orthopedics business. Madison Muller has more on "Bloomberg Open Interest.
Johnson & Johnson says focusing on improving performance of MedTech business
Expects stronger Q4 “and beyond” for MedTech.
Johnson & Johnson says continues to ‘invest strategically’ in R&D
Says Q3 results driven by innovative medicines business. Says drivers underpinning guidance “remain firmly in place.” “Remains confident” in FY26 guidance for $21B in free cash flow. Published first o...
Johnson & Johnson: Internal investments will propel double-digit growth by 2030
Says double-digit growth by the end of the decade guidance does not assume any inorganic additions.
Johnson & Johnson Earnings Call Transcript: Q3 2026
Q3 operational sales rose 6% to $25.4B, led by Innovative Medicine, while MedTech growth lagged expectations. FY 2026 sales guidance was raised, with adjusted EPS guidance of $10.95–$11.05 operationally and a continued path to double-digit growth by decade-end.
Johnson & Johnson Earnings release: Q3 2026
Johnson & Johnson released its Q3 2026 earnings on October 13, 2026, summarizing the period's financial results.